Moteur de recherche d’entreprises européennes
Financement de l’UE (4 000 000 €) : Études PanCare sur la mise à l’échelle et la mise en œuvre du passeport numérique de survie afin d’améliorer les soins centrés sur la personne pour les survivants … Hor 28/01/2021 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Études PanCare sur la mise à l’échelle et la mise en œuvre du passeport numérique de survie afin d’améliorer les soins centrés sur la personne pour les survivants du cancer pédiatrique
Almost 500,000 former childhood cancer patients (CCS) are now living in Europe. Compared to the general population, CCS represent a vulnerable population as they are at an increased risk of developing health problems, known as late effects, resulting in excess morbidity and mortality. Many survivors are unaware of their personal risk for specific late effects, which reduces their ability to manage their own follow-up care. Similarly, their treating healthcare professionals (HCPs) lack information about care required for CCS and access to treatment data from their childhood cancer. The Survivorship Passport (SurPass) is an innovative, digital tool, developed in previous EU-funded projects, that can be used to overcome these knowledge gaps to improve people-centred long-term survivorship care. Importantly, end users (CCS, HCPs) are integral to the research, represented by three key stakeholder networks (PanCare, SIOP Europe, CCI Europe). PanCareSurPass will conduct a robust assessment of the implementation of the SurPass by first conducting a pre-implementation study in six countries (Austria, Belgium, Germany, Italy, Lithuania, Spain) representing three infrastructural scenarios in Europe. Ethical, structural, organisational, economical, national, local, privacy issues, health systems, and particular national circumstances will be taken into account throughout. An Implementation Strategy will be developed and the SurPass will be updated and validated before use in an implementation study in the six countries. The study will look at a range of outcomes including CCS activation and empowerment, CCS/HCP satisfaction with the tool, feasibility and health economics. Based on the results of the study, a Prediction Model will be developed to promote and support future implementation of the SurPass across Europe.
| AIT Austrian Institute OF Technology GmbH | 116 250 € |
| Azienda Tutela Salute Liguria | 54 841 € |
| Childhood Cancer International | 62 125 € |
| Cineca Consorzio Interuniversitario | 278 125 € |
| Fundacion para La Investigacion del Hospital Universitario La Fe de La Comunidad Valenciana | 279 603 € |
| Gesundheit Osterreich GmbH | 206 500 € |
| HL7 Europe | 346 875 € |
| Istituto Giannina Gaslini | 490 000 € |
| Katholieke Universiteit Leuven | 255 000 € |
| Liguria Digitale S.p.A. | 0,00 € |
| Pancare | 76 625 € |
| Pintail Ltd. | 198 388 € |
| Prinses Maxima Centrum Voor Kinderoncologie B.V. | 200 375 € |
| Siop Europe | 55 313 € |
| ST. Anna Kinderkrebsforschung GmbH | 358 750 € |
| ST Anna Kinderkrebsforschung Verein | 0,00 € |
| Universitaetsmedizin DER Johannes Gutenberg-Universitaet Mainz | 580 103 € |
| Universitaet zu Luebeck | 198 523 € |
| Vilniaus Universiteto Ligonine Santaros Klinikos | 242 606 € |
https://cordis.europa.eu/project/id/899999
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
